ALX Oncology Holdings, Inc. (ALXO)
| Market Cap | 401.93M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -93.81M |
| Shares Out | 40.68M |
| EPS (ttm) | -2.32 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 124,976 |
| Open | 9.45 |
| Previous Close | 9.41 |
| Day's Range | 9.31 - 9.95 |
| 52-Week Range | 5.82 - 81.19 |
| Beta | n/a |
| Analysts | Buy |
| Price Target | 44.12 (+346.6%) |
| Earnings Date | Aug 11, 2022 |
About ALXO
ALX Oncology Holdings Inc., a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction... [Read more...]
Financial Performance
Financial StatementsAnalyst Forecast
According to 14 analysts, the average rating for ALXO stock is "Buy." The 12-month stock price forecast is 44.12, which is an increase of 346.56% from the latest price.
News
ALX's stock is up 11% after getting orphan-drug designation for cancer drug
Shares of ALX Oncology Holdings Inc. ALXO, -1.47% gained 11.5% in premarket trading on Wednesday after the company said it received an orphan-drug designation for evorpacept, its experimental acute myel...
ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Acute Myeloi...
SOUTH SAN FRANCISCO, Calif., June 29, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD...
ALX Oncology Announces Evorpacept Clinical Program Updates
– Expansion of solid tumor clinical program – ASPEN-02 dose optimization data to inform dosing for ASPEN-05
ALX Oncology Reports First Quarter 2022 Financial Results and Provides Clinical Development and Operational Highlights
SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD4...
ALX Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Clinical Development and Operat...
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD...
ALX Oncology's (ALXO) Evorpacept Gets Orphan Drug Tag for GC
The FDA bestows an Orphan Drug status to ALX Oncology's (ALXO) lead candidate, evorpacept, for treating gastric cancer and gastroesophageal junction cancer.
ALX Oncology Receives U.S. FDA Orphan Drug Designation for Evorpacept for the Treatment of Patients with Gastric Canc...
SOUTH SAN FRANCISCO, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD...
New Strong Sell Stocks for January 19th
ONEM, ALXO, and AVNS have been added to the Zacks Rank #5 (Strong Sell) List on January 19, 2022
ALX Oncology Provides Corporate Update and Highlights Key Milestones in 2022
SOUTH SAN FRANCISCO, Calif., Jan. 10, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD...
ALX Oncology's Evorpacept Data Fails To Impress At ASH Presentation
ALX Oncology Holdings Inc (NASDAQ: ALXO) presented initial clinical data from its ongoing Phase 1 / 2 trial evaluating evorpacept combined with azacitidine for untreated higher-risk or relapsed or refra...
ALX Oncology Announces Initial Data from ASPEN-02, the Ongoing Phase 1 / 2 Study of Evorpacept in Combination with Az...
-- Complete remissions with cytogenetic responses, hematologic improvement, and transfusion independence were observed in patients with previously untreated higher-risk MDS
ALX Oncology Reports Third Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights
SOUTH SAN FRANCISCO, Calif., Nov. 11, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD...
ALX Oncology Falls After Updated Data For Solid Tumors Candidate
ALX Oncology Holdings Inc (NASDAQ: ALXO) released additional data from a phase 1b trial of evorpacept in solid tumor malignancies. One cohort included gastric/gastroesophageal junction cancer patients r...
ALX Oncology to Present New Evorpacept Clinical Data in Myelodysplastic Syndromes at 63rd ASH Annual Meeting
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD4...
ALX Oncology Announces Upcoming Virtual Investor Conference Participation
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD...
ALX Oncology Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company, and ScalmiBio, Inc. (“ScalmiBio”) ann...
Zymeworks and ALX Oncology Announce First Patient Dosed in Phase 1b/2 Clinical Trial of Zanidatamab and Evorpacept (A...
VANCOUVER, British Columbia & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, and ALX On...
ALX Oncology Announces Initiation of Investigator-Sponsored Trial of Evorpacept (ALX148) in Patients with Indolent an...
-- Phase 1/2 study conducted at The University of Texas M.D. Anderson Cancer Center -- Phase 1/2 study conducted at The University of Texas M.D. Anderson Cancer Center
The 3 Best Biotech Stocks to Buy Right Now
Let your portfolio reflect your personality.
So What's Going On With ALX Oncology's Stock?
ALX Oncology Holdings Inc (NASDAQ: ALXO) shares are trading higher by 19.3% at $74.69, potentially in sympathy with Trillium Therapeutics which announced an acquisition by Pfizer Monday. ALX Oncology is...
ALX Oncology Reports Second Quarter 2021 Financial Results and Provides Clinical Development and Operational Highlights
BURLINGAME, Calif., Aug. 12, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkp...
ALX Oncology Announces First Patient Dosed in ASPEN-04, a Phase 2 Study of ALX148 in Combination with KEYTRUDA® (pemb...
The second of two distinct randomized Phase 2 studies in collaboration with Merck has been initiated The second of two distinct randomized Phase 2 studies in collaboration with Merck has been initiated
ALX Oncology Holdings Inc. (ALXO) Upgraded to Buy: Here's What You Should Know
ALX Oncology Holdings Inc. (ALXO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ALX Oncology (ALXO) Sees Hammer Chart Pattern: Time to Buy?
ALX Oncology (ALXO) has been struggling lately, but the selling pressure may be coming to an end soon.
Why Odonate Therapeutics, Opthea, ALX Oncology, Advaxis and Provention Bio Are Moving Today
Odonate Therapeutics, Inc. (NASDAQ: ODT), Opthea Limited (NASDAQ: OPT), ALX Oncology Holdings Inc. (NASDAQ: ALXO), Provention Bio, Inc. (NASDAQ: PRVB) and Advaxis, Inc. (NASDAQ: ADXS) are among the bigg...